anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method and a computing apparatus (110) for evaluating care quality and/or assessing patient safety. The computing apparatus (110) obtains an episode of care (EOC) for treating a medical condition of one or more patients, referred to as “a patient”. The EOC comprises a plurality of diagnostic events related to the treatment of the medical condition. The computing apparatus (110) collects, from at least one healthcare institution, information associated with said diagnostic events for the patient. The computing apparatus (110) obtains quality test results for at least two of the plurality of diagnostic events, referred to as “two diagnostic events”. Said two diagnostic events in the episode of care are associated with two standardized quality tests, respectively. Said two standardized tests are provided and monitored by a control organ. The computing apparatus (110) generates, for the EOC, at least one score based on the collected information and the quality test results. The computing apparatus (110) provides information indicative of said at least one score for use as evaluation and/or decision support for the treatment of the medical condition. A corresponding computer program and computer program carrier are also disclosed.
Thrombocytopenia in older individuals is a common but diagnostically challenging condition that has variable clinical impact to those who are affected. Diagnostic approach requires evaluation of the preexisting clinical conditions, detailed review of medications, and assessment for disorders that warrant urgent treatment. In this article, we describe a systematic approach to diagnosis of thrombocytopenia and present a schematic review for management strategies. Three clinical scenarios are presented that are relevant for their prevalence and management challenges in an older adult population. The first scenario addresses primary immune thrombocytopenia (ITP) and reviews different treatment options. The second one addresses complications of thrombocytopenia in management of the myelodysplastic syndrome. The last one reviews diagnostic challenges of drug-induced ITP.
Within 4-6 weeks after surgery and/or ablation, patients receive a continuous hepatic arterial infusion of floxuridine on days 1-14, oxaliplatin IV over 2 hours on day 22, and oral capecitabine twice daily on days 22-35. Treatment repeats every 42 days for 4 cycles in the absence of unacceptable toxicity. Beginning with cycle 5, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment with oxaliplatin and capecitabine repeats every 21 days for 4 cycles.
Participants that meet definition of MRD positivity at C16D1 will enter the triple therapy arm (zanubrutinib, venetoclax, and obinutuzumab). These participants will continue combination therapy with zanubrutinib and venetoclax, but will also receive 6 cycles of obinutuzumab starting at C17D1. In this subgroup, peripheral blood and bone marrow MRD assessments will occur after an additional 6 cycles of the triplet combination therapy (C23D1) at which point all participants will stop study treatment regardless of MRD status.
Analysis of data will be performed for participants who had have MPH (Concerta or Ritalin), ATO, or GFC first exposure between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any study drug(s) among the participants with an exposure to at least one of the study drugs.
FIELD: medicine. SUBSTANCE: the suggested innovation deals with treating disbacterioses and other intestinal disfunctions to improve biological balance of human gastrointestinal flora. The method deals with diagnostics and correction of patient's state based upon the diagnostics carried out. There are four stages of disbacteriosis depending upon patient's microflora state; one should prescribe its individual correction and perform complex impact upon patient's body due to detoxication with the help of enterosorbents, then comes correction with the help of probiotics, hepatic protection against toxic substances with the help of pectins and preparations made out of medicinal plants and maintenance-drug therapy with the help of antibacterial preparations of plant origin. Intake scheme and dosage vary depending upon the degree of patient's body microflora deviation against the norm. The method enables to perform individual approach to every patient and exclude relapses. EFFECT: higher efficiency of therapy. 4 ex
The invention relates to temporal interference removal and an improved heart rate measurement tracking mechanism. Heart rate monitors suffer from noisy photoplethysmography (PPG) data, making it difficult for the monitor to output consistently accurate heart rate readings. Noise is often caused by motion. It may be helpful, but not always, to measure movement using known methods of processing accelerometer readings to filter out some noise. The present disclosure describes generating a filter for filtering the PPG signal before tracking the frequency of the heartbeat (heart rate) based on an improved front-end technique (time-domain interference removal) using adaptive linear prediction on accelerometer data. The present disclosure also describes an improved back-end technique that is based on steering the frequency of the resonant filter to track the heartbeat. Implementing one or both of these techniques results in a more accurate heart rate measurement.
A method of selecting immunogens for inclusion in an immunogenic composition (vaccine) by identifying at least one variant of a reference (wild-type) immunogen. A language model is used to evaluate data from a plurality of variants and data representing the reference immunogen. A characteristic vector derived from an output feature map of a hidden layer of the language model is extracted. Dimension reduction is performed on each vector to generate a plurality of points, each point associated with a different variant. Clusters of variants are identified and a middle point for each cluster is calculated. A distance score for each variant is generated, derived from that variants vector and the middle point of at least one cluster of variants. A variant based on the distance score is identified and at least one immunogen is selected from at least one variant for inclusion in the vaccine. The variant can be identified using a pareto front. A further aspect is a method of making the vaccine composition using the above method. A further aspect is a vaccine created using the above method. The immunogen can be the spike protein of SARS-CoV-2. The immunogen can comprise SEQ ID Nos 1 to 10.
Writing is an essential element of literacy development, and language plays a central role in the composing process, including developing, organizing, and refining ideas. Language and writing are interconnected, making it paramount for educators to attend to the development of deaf students' language skills. In this quasi-experimental study, we examined the impact of strategic and interactive pedagogical approaches, namely Strategic and Interactive Writing Instruction, implemented with deaf students in grades 3-6 to develop genre-specific traits in their expressive language (spoken or signed) and writing. In this study, a total of 16 teachers and their 69 students participated in the treatment and comparison groups. Expressive language and writing samples were collected at the beginning and end of the year for three different genres. Students in the treatment group showed statistically significant gains in their expressive and written language for recount and information genres when compared to students in the comparison group. There was not a significant treatment effect on persuasive expressive language or writing. In addition, there was a significant positive correlation between expressive language and writing at both time points across all three genres. This study provides evidence on the importance of attending to language skills during literacy instruction.
Live donor liver transplantation (LDLT) has established itself as a treatment for end-stage liver disease but donor safety remains a major issue. It is the responsibility of the transplant team to restore donor's health, not only physical, but also mental, social and environmental. There is scarcity of long term longitudinal data on donor quality of life. Most of the studies are cross sectional which describe the quality of life at certain time point and do not take into account of changes that might occur over a period. It is more relevant in this scenario, as two persons from a family undergo surgery at the same time, which has a profound effect on family dynamics, and restoration towards normalcy goes hand in hand with adaptation to a new lifestyle. Another shortcoming of available literature is lack of uniform instruments which comprehensively measure the quality of life of live liver donors (LLDs). Standardized health related quality of life (HRQOL) instruments such as Short Form 36(SF 36) or World Health Organization quality of life Brief (WHOQOL-BREF) are not designed for LLDs. Moreover, there are several symptoms which might interfere with daily activities such as incision site problems , dyspepsia to name a few, but are not distressing enough to be reflected on quality of life scores .The aim of current study was to observe the attitude of donors pre transplant, quality of life over a period, satisfaction with the donation process, their assessment of the health care team, satisfaction with the consent process, and change in pattern of symptoms and cosmesis after surgery.
PCT No. PCT/GB80/00001 Sec. 371 Date Sep. 3, 1980 Sec. 102(e) Date Sep. 3, 1980 PCT Filed Jan. 4, 1980 PCT Pub. No. WO80/01381 PCT Pub. Date Jul. 10, 1980.Novel bicyclo [2,2,1] heptanes and hept-2Z-enes are substituted at the 5-position by a 6-carboxyhex-2-enyl group or a modification thereof, and at the 6-position by an aldoxime or ketoxime group which is O-substituted by an aliphatic hydrocarbon residue, an aromatic residue, or an aliphatic hydrocarbon residue substituted directly or through an oxygen or sulphur atom by an aromatic residue. Such compounds may be prepared by the action of an oximating agent on an intermediate which is substituted at the 6-position by an aldehydic or ketonic carbonyl group. The compounds are of value for use in pharmaceutical compositions particularly in the context of the inhibition of thromboxane activity.
TRISENOX is a sterile injectable solution of arsenic trioxide. The molecular formula of arsenic trioxide in the solid state is As2O3, with a molecular weight of 197.8 and the following structural formula:

TRISENOX is available in 10 mL, single-dose vials containing 12 mg of arsenic trioxide. TRISENOX is formulated as a sterile, nonpyrogenic, clear solution of arsenic trioxide in water for injection using sodium hydroxide and dilute hydrochloric acid to adjust to pH 8. TRISENOX is preservative-free. Arsenic trioxide, the active ingredient, is present at a concentration of 2 mg/mL. Inactive ingredients and their respective approximate concentrations are sodium hydroxide (1.2 mg/mL) for solubilization, and sodium hydroxide and hydrochloric acid for pH adjustment to pH 8.
The recommended adult oral dosage is one 8 mg ondansetron orally disintegrating tablet given twice a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. One 8 mg ondansetron orally disintegrating tablet should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.

###  Pediatric Use

For pediatric patients 12 years of age and older, the dosage is the same as for adults. For pediatric patients 4 through 11 years of age, the dosage is one 4 mg ondansetron orally disintegrating tablet given 3 times a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with subsequent doses 4 and 8 hours after the first dose. One 4 mg ondansetron orally disintegrating tablet should be administered 3 times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy.

###  Geriatric Use

The dosage is the same as for the general population.
Pulmonary fibrosis is an interstitial scarring disease of the lung characterized by poor prognosis and limited treatment options. Tissue transglutaminase 2 (TG2) is believed to promote lung fibrosis by crosslinking extracellular matrix components and activating latent TGFβ. This study assessed physiologic pulmonary function and metabolic alterations in the mouse bleomycin model with TG2 genetic deletion. TG2-deficient mice demonstrated attenuated the fibrosis and preservation of lung function, with significant reduction in elastance and increases in compliance and inspiratory capacity compared to control mice treated with bleomycin. Bleomycin induced metabolic changes in the mouse lung that were consistent with increased aerobic glycolysis, including increased expression of lactate dehydrogenase A and increased production of lactate, as well as increased glutamine, glutamate, and aspartate. TG2-deficient mice treated with bleomycin exhibited similar metabolic changes but with reduced magnitude. Our results demonstrate that TG2 is required for a typical fibrosis response to injury. In the absence of TG2, the fibrotic response is biochemically similar to wild-type, but lesions are smaller and lung function is preserved. We also show for the first time that profibrotic pathways of tissue stiffening and metabolic reprogramming are interconnected, and that metabolic disruptions in fibrosis go beyond glycolysis.
Visual search problems are often reported in children with Cerebral Visual Impairment (CVI). To tackle the clinical challenge of objectively differentiating CVI from other neurodevelopmental disorders, we developed a novel test battery. Visual search tasks were coupled with verbal and gaze-based measurements. Two search tasks were performed by children with CVI (n: 22; mean age (SD): 9.63 (.46) years) ADHD (n: 32; mean age (SD): 10.51 (.25) years), dyslexia (n: 28; mean age (SD): 10.29 (.20) years) and neurotypical development (n: 44; mean age (SD): 9.30 (.30) years). Children with CVI had more impaired search performance compared to all other groups, especially in crowded and unstructured displays and even when they had normal visual acuity. In-depth gaze-based analyses revealed that this group searched in overall larger areas and needed more time to recognize a target, particularly after their initial fixation on the target. Our gaze-based approach to visual search offers new insights into the distinct search patterns and behaviours of children with CVI. Their tendency to overlook targets whilst fixating on it, point towards higher-order visual function (HOVF) deficits. The novel method is feasible, valid, and promising for clinical differential-diagnostic evaluation between CVI, ADHD and dyslexia, and for informing individualized training.
The invention discloses an anti-colon cancer vaccine strain and a preparation method thereof. The anti-colon cancer vaccine strain is named as SVA-20 and is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, and the microorganism preservation number is as follows: CGMCC NO. 18698. The anti-colon cancer vaccine strain SVA-20 is obtained by naturally selecting attenuation and in vitro domestication. The virus can be produced on MRC-5 cell, has effects of resisting colon cancer tumor cell in vitro, and is prepared by mixing 1 × 10 14 The virus particles/kilogram are injected into colon cancer tumor-bearing mice intravenously, do not cause death and visible clinical symptoms, can regress tumors, and are safe and stable, and the effective period can reach 2 years. The invention provides a new technical means for the immunotherapy of tumors.
Blood glucose control systems are disclosed. A blood glucose control system can receive a glucose level signal from a glucose sensor operatively coupled to a subject. The system can decode encoded data of the glucose level signal to obtain the glucose level of the subject and the indication of the glucose trend. The system can automatically calculate the dose control signal using a control algorithm configured to calculate regular correction boluses of glucose control agent in response to at least the glucose level of the subject. The system can select a dose control signal encoding profile from a plurality of dose control signal encoding profiles and, based on the dose control signal encoding profile, encode the dose control signal such that the pump controller can read the dose control signal. The system can transmit an encoded dose control signal to the pump controller.
This randomised study aimed to understand if multidisciplinary internet-based interventions performed in group and individually are applicable for participants suffering from longterm COVID-19 syndrome. Data will be collected by internet platform at Karolinska Institutet (BASS) before, after rehabilitation and at follow-up after 6 months. Both self-scored questionnaires and physical tests performed at home will be collected to understand the symptomatology, functioning and activity level. Rehabilitation during 8 weeks period will be given in groups as face-to-group, pre-recorded film sessions and by individual approach, the participants will use ExorLive app for physical activity.

The participants will be randomised for treatment and waiting lists using a website random.org. Waiting list will be offered rehabilitation interventions after at least 8 weeks period of waiting to exclude a spontaneous improvement or worsening of symptoms. To understand the impact of rehabilitation on work capacity and employment/economic supply, the data from Social Insurance databas will be obtained 2021 year before and upp to 2 years after the intervention. To understand the impact of rehabilitation on sickness-leave, the data from National Insurance Agency will be obtained for 2021 and 2022.
Iron homeostasisis is integral to normal physiological and biochemical processes of lungs. The maintenance of iron homeostasis involves the process of intake, storage and output, dependening on iron-regulated protein/iron response element system to operate tightly metabolism-related genes, including TFR1, DMT1, Fth, and FPN. Dysregulation of iron can lead to iron overload, which increases the virulence of microbial colonisers and the occurrence of oxidative stress, causing alveolar epithelial cells to undergo necrosis and apoptosis, and form extracellular matrix. Accumulated iron drive iron-dependent ferroptosis to exacerbated pulmonary fibrosis. Notably, the iron chelator deferoxamine and the lipophilic antioxidant ferritin-1 have been shown to attenuate ferroptosis and inhibit lipid peroxidation in pulmonary fibrosis. The paper summarises the regulatory mechanisms of dysregulated iron metabolism and ferroptosis in the development of pulmonary fibrosis. Targeting iron metabolism may be a potential therapeutic strategy for the prevention and treatment of pulmonary fibrosis.
PROBLEM TO BE SOLVED: To obtain the subject composition in which eperisone or tolperisone is formulated, capable of bringing about sufficient effect and scarcely producing adverse effect by formulating at least one kind of compound selected from eperisone or tolperisone with vitamins. SOLUTION: This composition for external use is obtained by formulating (A) at least one kind of compound selected from eperisone and tolperisone with (B) vitamins. Vitamin A palmitate, vitamin K3, tocopherol, ubiquinone, coenzyme type vitamin B12, biotin, vitamin Es, etc., is exemplified as the component B and vitamin Es (tocopherol, tocopherol acetate, tocopherol nicotinate, tocopherol succinate, etc.), is preferable among them and especially, tocopherol acetate is preferable. Preferable formulation amounts of the component A and the component B to total amount of the composition are each 0.1-5.0 wt.% and 0.001-5.0 wt.%. The formulation amount of the component B to 1 pt.wt. component A is preferably 0.001-3.0 pts.wt.
Chlordiazepoxide Hydrochloride has antianxiety, sedative, appetite-stimulating and weak analgesic actions. The precise mechanism of action is not known. The drug blocks EEG arousal from stimulation of the brain stem reticular formation. It takes several hours for peak blood levels to be reached and the half-life of the drug is between 24 and 48 hours. After the drug is discontinued plasma levels decline slowly over a period of several days. Chlordiazepoxide is excreted in the urine, with 1% to 2% unchanged and 3% to 6% as conjugate.

Animal Pharmacology

The drug has been studied extensively in many species of animals and these studies are suggestive of action on the limbic system of the brain, which recent evidence indicates is involved in emotional responses.

Hostile monkeys were made tame by oral drug doses which did not cause sedation. Chlordiazepoxide Hydrochloride revealed a “taming” action with the elimination of fear and aggression. The taming effect of chlordiazepoxide hydrochloride was further demonstrated in rats made vicious by lesions in the septal area of the brain. The drug dosage which effectively blocked the vicious reaction was well below the dose which caused sedation in these animals.

The LD 50 of parenterally administered chlordiazepoxide hydrochloride was determined in mice (72 hours) and rats (5 days), and calculated according to the method of Miller and Tainter, with the following results: mice, IV, 123±12mg/kg; mice, IM, 366±7mg/kg; rats, IV, 120±7 mg/kg; rats, IM, >160 mg/kg. 

Effects on Reproduction

Reproduction studies in rats fed 10, 20 and 80 mg/kg daily and bred through one or two matings showed no congenital anomalies, nor were there adverse effects on lactation of the dams or growth of the newborn. However, in another study at 100 mg/kg daily there was noted a significant decrease in the fertilization rate and a marked decrease in the viability and body weight of offspring which may be attributable to sedative activity, thus resulting in lack of interest in mating and lessened maternal nursing and care of the young. One neonate in each of the first and second matings in the rat reproduction study at the 100 mg/kg dose exhibited major skeletal defects. Further studies are in progress to determine the significance of these findings.
Sepsis is a global health problem; progression to septic shock is associated with a marked increase in morbidity and mortality. In this setting, increased plasma lactate levels demonstrated to be an indicator of severity and a predictor of mortality, and are usually interpreted almost exclusively as a marker of low tissue perfusion. However, a recent paradigm shift has occurred in the exegesis of lactate metabolism and its biological properties. Indeed, metabolic adaptation to stress, even with an adequate oxygen supply, may account for high circulating lactate levels. Likewise, other pathophysiological consequences of sepsis, such as mitochondrial dysfunction, are associated with the development of hyperlactatemia, which is not necessarily accompanied by low tissue perfusion. Interpreting the origin and function of lactate may be of great clinical utility in sepsis, especially when circulating lactate levels are the basis for resuscitative measures.